BSE filing, NSE: ASPIRA. Summary written from the filing by ALFA Finder's alert engine.
Aspira Pathlab & Diagnostics Ltd: key numbers
- Share price
- ₹133.80
- Market cap
- ₹137.7 Cr
- Revenue (annual)
- ₹24.98 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- -304.3×Sector 52.8×
- Promoter holding
- 46.65%+0.07% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aspira Pathlab & Diagnostics Ltd
All →Aspira Pathlab & Diagnostics Board Meeting Date
Aspira Pathlab & Diagnostics will hold a board meeting on November 6, 2026 to consider unaudited standalone results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after the results.
Aspira Pathlab & Diagnostics Other Announcement
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Listing Regulations.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.02 Cr
Promoter Jay Arvind Bhanushali acquired 1,424 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. The transaction is valued at ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,424 shares of Aspira Pathlab & Diagnostics Ltd via the open market. This transaction increased the promoter's stake from 7.27% to 7.28%.
- Execution
- 17-09-2026 to 24-09-2026
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Annual General Meeting
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.01 Cr
Promoter Jay Arvind Bhanushali acquired 1,387 equity shares of Aspira Pathlab & Diagnostics Ltd through market purchase, increasing their stake from 7.25% to 7.27%.
- Value
- ₹0.01 Cr
- Promoter stake change
- +0.02%
Other debt & borrowing announcements
All →Neogen Chemicals Debt & Borrowing: ₹500 Cr
Neogen Chemicals approved in-principle a Rs 500 Crore corporate guarantee for Neogen Morita's borrowings, subject to shareholder approval. The company reports no adverse impact.
- Value
- ₹500.0 Cr
Satin Creditcare Network Debt & Borrowing: ₹1.83 Cr
Satin Creditcare paid Rs.1.83 Crore quarterly interest on its 10.40% April 2027 NCDs on 31 October 2026. The payment fulfils an existing debt obligation.
- Value
- ₹1.83 Cr
AAA Technologies Debt & Borrowing: ₹6 Cr
AAA Technologies approved an inter-corporate loan of up to Rs.6 Crore to Transaction Solutions International at 12% interest. Repayable on demand; share-pledge security is proposed.
- Value
- ₹6.00 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹12.5 Cr
Spandana Sphoorty partially redeemed Rs 12.50 Crore of its listed secured NCDs on 31 October 2026 by face-value redemption. Rs 200 Crore remains outstanding.
- Value
- ₹12.50 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹2.71 Cr
Spandana Sphoorty paid monthly interest of Rs 2.71 Crore across two listed secured NCD series on 30 October 2026, on time. Series-wise amounts were Rs 2.01 Crore and Rs 0.70 Crore.
- Value
- ₹2.71 Cr
Industrial Investment Trust Debt & Borrowing: ₹200 Cr
Industrial Investment Trust's board approved borrowing up to Rs. 200 Crore from banks, NBFCs and other lenders, within the Rs. 1,000 Crore shareholder limit. The enabling approval names no specific lender yet.
- Value
- ₹200.0 Cr